A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults

NCT06452771 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers With Hyperlipidemia

Interventions

DRUG: ALN-ANG3
DRUG: Placebo (PB)

Sponsor

Regeneron Pharmaceuticals